Remdesivir

Regional News • Americas • United States
Remdesivir approved as first Covid-19 treatment by US FDA
Remdesivir approved as first Covid-19 treatment by US FDA
Credit: unsplash.com / Dimitri Karastelev

The US Food and Drug Administration (FDA) has approved Remdesivir, a broad-spectrum antiviral medication, as the first Covid-19 treatment. According to a study by U.S. National Institutes of Health, Remdesivir can cut the time of recovery from 15 to 10 days.

Regional News • Americas • United States
Trump is doing "very well", White House physician says
Trump is doing "very well", White House physician says
Credit: @PressSec, Courtesy of Twitter

President Donald Trump, who was flown to Walter Reed National Military Medical Center on Friday after testing positive for Covid-19, is doing "very well" and has started Remdesivir therapy, according to a statement by Press Secretary Kayleigh McEnany.

"This afternoon, in consultation with specialists from Walter Reed and Johns Hopkins University, I recommended movement of the President up to Walter Reed National Military Medical Center for further monitoring. This evening I am happy to report that the President is doing very well. He is not requiring any supplemental oxygen, but in consultation with specialists, we have elected to initiate Remdesivir therapy. He has completed his first dose and is resting comfortably," the statement reads.

Trump has since tweeted for the first time since arriving at Reed Medical Center, writing: "Going welI[sic], I think! Thank you to all. LOVE!!!"

Business • Health Care
EU secures 30,000 doses of Covid-19 drug
Remdesivir
Remdesivir Credit: Dimitri Karastelev

Despite uncertainties in the effectiveness of treatment with Remdesivir, the European Commission has secured from US-based Gilead 30,000 doses on a 63 million contract.
Remdesivir is the first drug to be approved in the European Union for the treatment of Covid-19.

Science • Medicine
Gilead announces start of clinical testing for an inhaled solution of Remdesivir
Gilead announces start of clinical testing for an inhaled solution of Remdesivir
Credit: unsplash.com/CDC

Biopharmaceutical company Gilead Sciences Inc. announced that trials for its inhaled solution of Remdesivir have begun. The randomised, placebo-controlled trial will be tested on 60 healthy patients between the ages of 18-45 to determine the safety, tolerability and pharmacokinetics of the drug.

"With promising data emerging from the randomized, clinical trials of intravenous remdesivir administered to hospitalized patients, it became clear that efforts were needed to investigate the drug’s potential in the outpatient setting. Significant research efforts have been undertaken to deliver remdesivir in an inhaled, nebulized format," so Chief Medical Officer Dr. Merdad Parsey.

Regional News • Americas • United States
Remdesivir out of stock as United States buy world wide supplies
Remdesivir out of stock as United States buy world wide supplies
Credit: unsplash.com/Christina Victoria Craft

One of the two drugs that have been approved for the treatment of Covid-19, Remedesivir, has been bought up by the United States. For the next three months, there will most likely be almost no supply for other countries. According to Dr Andrew Hill from Liverpool University, the United States "got access to most of the drug supply" of Remdesivir. Over 500,000 doses have been bought.

Alex Azar, the United States health and human services secretary has stated that "to the extent possible, we want to ensure that any American patient who needs Remdesivir can get it. The Trump administration is doing everything in our power to learn more about life-saving therapeutics for Covid-19 and secure access to these options for the American people".